Bluebird Bio, Inc. BLUE got an unsolicited, non-binding composed proposition from Ayrmid Ltd. on Friday.
Ayrmid has actually proposed to get Bluebird for an in advance money payment of $4.50 per share and a one-time contingent worth right of $6.84 per share payable upon attaining a net sales turning point.
In February 2025, Bluebird participated in a conclusive arrangement with Carlyle and SK Capital Partners to be gotten and taken personal for $3.00 per share in money and a one-time contingent worth right of $6.84 per share payable upon accomplishment of a net sales turning point.
Likewise Check Out: FDA-Approved Sickle Cell Treatments From Bluebird Bio And Vertex Join Medicaid Development Program
Bluebird formerly took part in conversations with Ayrmid as part of its detailed evaluation of tactical options.
Ayrmid did not send any proposition to Bluebird throughout that procedure.
Constant with its fiduciary tasks, the Bluebird Board of Directors is examining the Ayrmid Proposition in assessment with its legal and monetary consultants.
In November 2024, the FDA raised issues about dangerous hematologic malignancies in clients treated with Bluebird Bio’s Skysona (elivaldogene autotemcel), a gene treatment for early, active cerebral adrenoleukodystrophy (CALD).
The company has actually gotten reports of myelodysplastic syndrome and severe myeloid leukemia connected to Skysona, with cases emerging 14 to 92 months post-treatment throughout medical trials.
Rate Action: BLUE stock is up 7.84% at $4.40 at the last check Monday.
Read Next:
Image: Shutterstock
Momentum 2.85
Development–
Quality–
Worth 31.86
Market News and Data gave you by Benzinga APIs